| Basics |
Neurocrine Biosciences, Inc.
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
|
| IPO Date: |
May 23, 1996 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$12.14B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.84 | 1.98%
|
| Avg Daily Range (30 D): |
$1.41 | 1.24%
|
| Avg Daily Range (90 D): |
$1.54 | 1.37%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.69M |
| Avg Daily Volume (30 D): |
1.3M |
| Avg Daily Volume (90 D): |
1.25M |
| Trade Size |
| Avg Trade Size (Sh.): |
96 |
| Avg Trade Size (Sh.) (30 D): |
45 |
| Avg Trade Size (Sh.) (90 D): |
47 |
| Institutional Trades |
| Total Inst.Trades: |
11,706 |
| Avg Inst. Trade: |
$3.67M |
| Avg Inst. Trade (30 D): |
$7.85M |
| Avg Inst. Trade (90 D): |
$8.72M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$8.53M |
| Avg Closing Trade (30 D): |
$25.32M |
| Avg Closing Trade (90 D): |
$24.83M |
| Avg Closing Volume: |
95.69K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$.08
|
$1.28
|
|
Diluted EPS
|
|
$.08
|
$1.24
|
|
Revenue
|
$
|
$ 572.6M
|
$ 622.1M
|
|
Gross Profit
|
$
|
$ 563.4M
|
$ 614.1M
|
|
Net Income / Loss
|
$
|
$ 7.9M
|
$ 129.8M
|
|
Operating Income / Loss
|
$
|
$ 23.6M
|
$ 183.8M
|
|
Cost of Revenue
|
$
|
$ 9.2M
|
$ 8M
|
|
Net Cash Flow
|
$
|
$ -38.9M
|
$ 209.4M
|
|
PE Ratio
|
|
|
|
|
